Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. The causes of Atopic dermatitis (AD) is unknown but believed to involve genetics, immune system dysfunction, environmental exposures, and difficulties with the permeability of the skin. If one identical twin is affected, there is an 85% chance the others also have the condition. Those who live in cities and dry climates are more commonly affected. Exposure to certain chemicals or frequent hand washing makes symptoms worse. While emotional stress may make the symptoms are worse. The disorder is not contagious. The diagnosis is typically based on the signs and symptoms.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-market
The Atopic Dermatitis market report also covers emerging drugs, current treatment practices, Atopic Dermatitis market share of the individual therapies, current and forecasted Atopic Dermatitis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Atopic Dermatitis Market Key Facts
-
As per the National Eczema Association 2019, Atopic dermatitis (AD) is the most common type of eczema. In fact, more than 18 million American adults have atopic dermatitis which often appears as a red, itchy rash normally on the cheeks, arms, and legs.
-
As per DelveInsight estimates, a higher prevalent population of uncontrolled Atopic Dermatitis is observed in the United States as compared to EU5 countries and Japan.
-
As per the study conducted by Yifeng Guo et al. 2016, titled “Prevalence of Atopic Dermatitis in Chinese Children Aged 1–7 ys” The proportion of mild, moderate, and severe AD is 74.60%, 23.96%, and 1.44% respectively.
-
According to DelveInsight’s findings, females are affected more as compared to males, in the case of Atopic Dermatitis.
Key Benefits of Atopic Dermatitis Market Report
-
Atopic Dermatitis market report provides an in-depth analysis of Atopic Dermatitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Atopic Dermatitis market report will help in developing business strategies by understanding the Atopic Dermatitis Market trends & developments, key players, and future market competition that will shape and drive the Atopic Dermatitis market in the upcoming years.
-
The Atopic Dermatitis market report covers Atopic Dermatitis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Atopic Dermatitis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Atopic Dermatitis market size is expected to increase during the forecast period owing to the rise in the number of Prevalent cases of Atopic Dermatitis patients in the 7MM.
The Atopic Dermatitis market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Atopic Dermatitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Atopic Dermatitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Atopic Dermatitis Epidemiology
As per the Delveinsight, in the United States, the prevalent population of Atopic Dermatitis was found to be 19,460,609 in 2017.
The Atopic Dermatitis epidemiology section covers insights about the historical and current Atopic Dermatitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Atopic Dermatitis Drugs Uptake and Key Market Players
The Atopic Dermatitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis market or expected to get launched in the market during the study period. The analysis covers Atopic Dermatitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Atopic Dermatitis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecast period.
Atopic Dermatitis Companies:
Pfizer
Novartis Pharmaceuticals
Daiichi Sankyo
AbbVie
PurGenesis Technologies
And many others.
Atopic Dermatitis Therapies Covered in the Report Include:
Abrocitinib
ZPL389
DS-2741a
Upadacitinib
PUR0110
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Atopic Dermatitis Competitive Intelligence Analysis
4. Atopic Dermatitis Market Overview at a Glance
5. Atopic Dermatitis Disease Background and Overview
6. Atopic Dermatitis Patient Journey
7. Atopic Dermatitis Epidemiology and Patient Population
8. Atopic Dermatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Atopic Dermatitis Unmet Needs
10. Key Endpoints of Atopic Dermatitis Treatment
11. Atopic Dermatitis Marketed Products
12. Atopic Dermatitis Emerging Therapies
13. Atopic Dermatitis Seven Major Market Analysis
14. Attribute Analysis
15. Atopic Dermatitis Market Outlook (7 major markets)
16. Atopic Dermatitis Access and Reimbursement Overview
17. KOL Views on the Atopic Dermatitis Market.
18. Atopic Dermatitis Market Drivers
19. Atopic Dermatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Atopic Dermatitis (AD) Epidemiology Forecast
DelveInsight’s Atopic Dermatitis (AD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Atopic Dermatitis (AD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Atopic Dermatitis (AD) Pipeline Insights
Atopic Dermatitis (AD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Atopic Dermatitis (AD) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/